1. Home
  2. OMER vs AOMR Comparison

OMER vs AOMR Comparison

Compare OMER & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • AOMR
  • Stock Information
  • Founded
  • OMER 1994
  • AOMR 2018
  • Country
  • OMER United States
  • AOMR United States
  • Employees
  • OMER N/A
  • AOMR N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • AOMR Real Estate Investment Trusts
  • Sector
  • OMER Health Care
  • AOMR Real Estate
  • Exchange
  • OMER Nasdaq
  • AOMR Nasdaq
  • Market Cap
  • OMER 274.3M
  • AOMR 224.3M
  • IPO Year
  • OMER 2009
  • AOMR 2021
  • Fundamental
  • Price
  • OMER $4.48
  • AOMR $9.37
  • Analyst Decision
  • OMER Strong Buy
  • AOMR Strong Buy
  • Analyst Count
  • OMER 5
  • AOMR 6
  • Target Price
  • OMER $18.00
  • AOMR $11.25
  • AVG Volume (30 Days)
  • OMER 933.6K
  • AOMR 110.8K
  • Earning Date
  • OMER 11-12-2025
  • AOMR 11-05-2025
  • Dividend Yield
  • OMER N/A
  • AOMR 13.73%
  • EPS Growth
  • OMER N/A
  • AOMR N/A
  • EPS
  • OMER N/A
  • AOMR 1.56
  • Revenue
  • OMER N/A
  • AOMR $57,661,000.00
  • Revenue This Year
  • OMER N/A
  • AOMR N/A
  • Revenue Next Year
  • OMER N/A
  • AOMR $12.91
  • P/E Ratio
  • OMER N/A
  • AOMR $5.96
  • Revenue Growth
  • OMER N/A
  • AOMR N/A
  • 52 Week Low
  • OMER $2.95
  • AOMR $7.36
  • 52 Week High
  • OMER $13.60
  • AOMR $10.88
  • Technical
  • Relative Strength Index (RSI)
  • OMER 56.41
  • AOMR 41.20
  • Support Level
  • OMER $4.07
  • AOMR $9.29
  • Resistance Level
  • OMER $4.72
  • AOMR $9.60
  • Average True Range (ATR)
  • OMER 0.23
  • AOMR 0.14
  • MACD
  • OMER 0.02
  • AOMR -0.03
  • Stochastic Oscillator
  • OMER 61.19
  • AOMR 14.55

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About AOMR Angel Oak Mortgage REIT Inc.

Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.

Share on Social Networks: